Risk Stratification for Patients with Myelodysplastic Syndrome

SH-201 is a new, promising option for certain types of leukemias, including chronic myeloid leukemia and acute lymphoblastic leukemia, as well as other cancers.

Revumenib shows promise in treating both adults and children with specific types of leukemia, with similar safety and effectiveness.

Adam de Smith, PhD, discussed findings from a study investigating a genetic variant that increases the risk of acute lymphoblastic leukemia in Hispanic/Latino pediatric patients. 

Betty Hamilton, MD, discussed findings from a quality of life study in patients with FLT3 ITD-positive acute myeloid leukemia who underwent allogeneic stem cell transplant.

A phase 1/2 trial showed that SLS009 in combination with azacitidine and venetoclax achieved a 50% response rate in relapsed/refractory acute myeloid leukemia.

Revumenib, a first-in-class Menin inhibitor, was granted priority review from the FDA for the treatment of adult and pediatric relapsed or refractory KMT2A-rearranged acute leukemia.